Pulmonary arterial hypertension (PAH) is a progressive and fatal disease without a cure.
The exact pathogenic mechanisms of PAH are complex and poorly understood, yet a …

Mammalian target of rapamycin (mTOR) is a major regulator of cellular metabolism,
proliferation, and survival that is implicated in various proliferative and metabolic diseases …

Background—Enhanced proliferation, resistance to apoptosis, and metabolic shift to
glycolysis of pulmonary arterial vascular smooth muscle cells (PAVSMCs) are key …

Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial
smooth muscle cells is an important pathological cause for the elevated pulmonary vascular …

Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling,
increased pulmonary artery (PA) pressure, right-heart afterload and death. Mechanistic …

Pulmonary arterial vascular smooth muscle (PAVSM) cell proliferation is a key
pathophysiological component of vascular remodeling in pulmonary arterial hypertension …

Pulmonary arterial hypertension (PAH) is a progressive and fatal disease with no cure.
Pulmonary arterial pressure (PAP) is a function of cardiac output and pulmonary vascular …

Activation of the mammalian target of rapamycin complex 1 (mTORC1) subunit Raptor
induces cell growth and is a downstream target of Akt. Elevated levels of aldosterone …

Pulmonary artery (PA) smooth muscle cell (SMC) proliferation in pulmonary hypertension
(PH) may be linked to dysregulated mammalian target of rapamycin (mTOR) signaling. The …

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disorder with
high morbidity and mortality, and is characterized by excessive growth of endothelial cells …